Review of Immune-Related Adverse Events in Prostate Cancer Patients Treated with Ipilimumab: MD Anderson Experience

Targeting a T cell inhibitory checkpoint with the anti-CTLA-4 monoclonal antibody, ipilimumab, represents a scientific breakthrough in immunotherapy for the treatment of cancer. However, ipilimumab therapy is also associated with unique side effects, known as immune-related adverse events (irAEs), w...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Jianjun, He, Qiuming, Subudhi, Sumit, Aparicio, Ana, Zurita-Saavedra, Amado, Lee, Da Hyun, Jimenez, Camilo, Suarez-Almazor, Maria, Sharma, Padmanee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4530091/
https://www.ncbi.nlm.nih.gov/pubmed/25659583
http://dx.doi.org/10.1038/onc.2015.5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4530091/
https://www.ncbi.nlm.nih.gov/pubmed/25659583
http://dx.doi.org/10.1038/onc.2015.5

Ejemplares similares